Dehydroepiandrosterone in systemic lupus erythematosus

Current Rheumatology Reports

Volumn 10, Issue 4, 2008, Pages 286-291

  Sawalha, Amr H ^a   Kovats, Susan ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; PLACEBO; PRASTERONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ACNE; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROGEN THERAPY; BIOLOGICAL ACTIVITY; BONE MARROW CELL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HIRSUTISM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MOLECULAR MECHANICS; NONHUMAN; QUALITY OF LIFE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; ANIMAL; ARTICLE; BLOOD; DISEASE MODEL; FEMALE; IMMUNOLOGY; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; CYTOKINES; DEHYDROEPIANDROSTERONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 53249100912     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0046-1     Document Type: Review

References (52)

1. Dillon JS: Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: Their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005, 4:377-385.
2. Chen CC, Parker CR Jr: Adrenal androgens and the immune system. Semin Reprod Med 2004, 22:369-377.
3. Masi AT, Da Silva JA, Cutolo M: Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Baillieres Clin Rheumatol 1996, 10:295-332.
4. Hedman M, Nilsson E, de la Torre B: Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 1989, 7:583-588.
5. Lahita RG, Bradlow HL, Ginzler E, et al.: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987, 30:241-248.
6. Widstrom RL, Dillon JS: Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Semin Reprod Med 2004, 22:289-298.
7. Liu D, Dillon JS: Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha (i2,3). J Biol Chem 2002, 277:21379-21388.
8. Liu D, Dillon JS: Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: Evidence for a cell surface receptor. Steroids 2004, 69:279-289.
9. Ashida K, Goto K, Zhao Y, et al.: Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochim Biophys Acta 2005, 1728:84-94.
10. Meikle AW, Dorchuck RW, Araneo BA, et al.: The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992, 42:293-304.
11. McLachlan JA, Serkin CD, Bakouche O: Dehydroepiandrosterone modulation of lipopolysaccharide-stimulated monocyte cytotoxicity. J Immunol 1996, 156:328-335.
12. Loria RM: Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 2002, 67:953-966.
13. Loria RM, Padgett DA: Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol 1992, 127:103-115.
14. Aarrar D, Kuebler JF, Wang P, et al.: DHEA: a novel adjunct for the treatment of male trauma patients. Trends Mol Med 2001, 7:81-85.
15. Nalbandian G, Kovats S: UnderstaEding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol Res 2005, 31:91-106.
16. Kovats S, Carreras E: Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell Immunol 2008 (Epub ahead of print).
17. Straub RH: The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574.
18. Olsen NJ, Kovacs WJ: Effects of androgens on T and B lymphocyte development. Immunol Res 2001, 23:281-288.
19. Schmidt M, Kreutz M, Loffler G, et al.: Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol 2000, 164:161-169.
20. Hammer F, Drescher DG, Schneider SB, et al.: Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging. J Clin Endocrinol Metab 2005, 90:6283-6289.
21. RajuAR, Bland KI, Chaudry IH: Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol Med 2008, 14:213-221.
22. Straub RH, Konecna L, Hrach S, et al.: Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998, 83:2012-2017.
23. Daynes RA, Araneo BA, Ershler WB, et al.: Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993, 150:5219-5230.
24. Delpedro AD, Barjavel MJ, Mamdouh Z, Bakouche O: Activation of human monocytes by LPS and DHEA. J Interferon Cytokine Res 1998, 18:125-135.
25. Suzuki T, Suzuki N, Daynes RA, Engleman EG: Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991, 61:202-211.
26. Okabe T, Haji M, Takayanagi R, et al.: Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995, 80:2993-2996.
27. Murakawa Y, Takada S, Ueda Y, et al.: Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 1985, 134:187-195.
28. Solomou EE, Juang YT, Gourley MF, et al.: Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001, 166:4216-4222.
29. Tenbrock K, Tsokos GC: Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol 2004, 23:333-345.
30. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC: Altered signal transduction in SLE T cells. Rheumatology (Oxford) 2007, 46:1525-1530.
31. Suzuki T, Suzuki N, Engleman EG, et al.: Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995, 99:251-255.
32. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998, 273:32833-32841.
33. Du C, Khalil MW, Sriram S: Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol 2001, 167:7094-7101.
34. Dashtaki R, Whorton AR, Murphy TM, et al.: Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther 1998, 285:876-883.
35. Grammer AC, Fischer R, Lee O, et al.: Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004, 6:28-38.
36. Lucas JA, Ahmed SA, Casey ML, MacDonald PC: Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 1985, 75:2091-2093.
37. Matsunaga A, Miller BC, Cottam GL: Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: Lack of an effect on associated immunological abnormalities. Biochim Biophys Acta 1989, 992:265-271.
38. Yang BC, Liu CW, Chen YC, Yu CK: Exogenous dehydroepiandrosterone modified the expression of T helper-related cytokines in NZB/NZW F1 mice. Immunol Invest 1998, 27:291-302.
39. Norton SD, Harrison LL, Yowell R, Araneo BA: Administration of dehydroepiandrosterone sulfate retards onset but not progression of autoimmune disease in NZB/W mice. Autoimmunity 1997, 26:161-171.
40. Roubinian JR, Talal N, Greenspan JS, et al.: Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979, 63:902-911.
41. Olech E, MerrillTJT: DHEA supplementation: the claims in perspective. Cleve Clin J Med 2005, 72:965-966, 968, 970-971 passim.
42. van Vollenhoven RF, Engleman EG, McGuire JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1305-1310.
43. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL: Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998, 25:285-289.
44. van Vollenhoven RF, Engleman EG, McGuire JL: Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995, 38:1826-1831.
45. van Vollenhoven RF, Park JL, Genovese MC, et al.: A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999, 8:181-187.
46. Formiga F, Moga I, Nolla JM, et al.: The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol 1997, 15:387-392.
47. Hartkamp A, Geenen R, Godaert GL, et al.: The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum 2004, 50:3591-3595.
48. Chang DM, Lan JL, Lin HY, Luo SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2002, 46:2924-2927.
49. Petri MA, Lahita RG, Van Vollenhoven RF, et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002, 46:1820-1829.
50. Petri MA, Mease PJ, Merrill JT, et al.: Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004, 50:2858-2868.
51. Nordmark G, Bengtsson C, Larsson A, et al.: Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005, 38:531-540.
52. van Leuven SI, Kastelein JJ, D'Cruz DP, et al.: Atherogenesis in rheumatology. Lupus 2006, 15:117-121.